問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃怡璇

Recruiting

List

30Cases

2025-08-01 - 2030-12-31

Phase I

Active
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)

  • Condition/Disease

    Neoplasms

  • Test Drug

    錠劑

Participate Sites
2Sites

Recruiting2Sites

2025-09-01 - 2031-08-14

Phase I/II

Active
A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer

  • Condition/Disease

    Advanced Lung Cancer

  • Test Drug

    靜脈輸注液 溶液用粉劑

Participate Sites
5Sites

Recruiting5Sites

2025-10-01 - 2028-12-31

Phase I/II

Active
An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC)

  • Condition/Disease

    Colorectal Cancer (Diagnosis)

  • Test Drug

    膠囊劑 靜脈輸注液 靜脈輸注液 膠囊劑

Participate Sites
7Sites

Recruiting7Sites

2025-11-01 - 2027-08-22

Phase II

Active
A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease

  • Condition/Disease

    Drug-Related Side Effects and Adverse Reactions

  • Test Drug

    皮下注射劑

Participate Sites
5Sites

Recruiting5Sites

2025-11-14 - 2029-06-30

Phase I

Not yet recruiting
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors

  • Condition/Disease

    NSCLC Adenocarcinoma

  • Test Drug

    錠劑 膠囊劑 錠劑

Participate Sites
4Sites

Recruiting4Sites

2025-04-01 - 2033-01-20

Active
A phase 3, multicenter, randomized, open-label trial evaluating trastuzumab deruxtecan plus pembrolizumab versus platinum-based chemotherapy plus pembrolizumab as first-line therapy in participants with locally advanced, unresectable or metastatic HER2 overexpression and PD-L1 TPS <50% non-squamous non-small cell lung cancer (DESTINY-Lung06).

  • Condition/Disease

    The efficacy of T-DXd with pembrolizumab versus platinum-based chemotherapy with pembrolizumab was compared using PFS as assessed by BICR. PFS was defined as the time interval elapsed from the date of randomization to the date of radiographic disease progression or death from any cause. Tumor response was assessed by BICR tumor scans and determined using the Solid Tumor Response Assessment Criteria, version 1.1 (RECIST v1.1).

  • Test Drug

    Trastuzumab Deruxtecan

Participate Sites
9Sites

Recruiting9Sites

2025-05-01 - 2030-04-30

Phase III

Active
A global, multicenter, randomized, open-label phase 3 trial comparing sacituzumab govitecan with standard of care (SOC) in previously treated extensive-stage small cell lung cancer (ES-SCLC) participants.

  • Condition/Disease

    ORR is defined as the percentage of participants who achieve a complete response (CR) or a partial response (PR) as assessed by BICR according to RECIST v1.1. OS is defined as the length of time elapsed from random assignment until the date of death from any cause.

  • Test Drug

    TRODELVY for Injection

Participate Sites
9Sites

Recruiting9Sites

2026-05-01 - 2027-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-09-01 - 2032-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-11-01 - 2029-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB